BeiGene to Present at Upcoming Investor Conferences
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,today announced that the Company will participate in two upcoming investor conferences: The Guggenheim Oncology
Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,today announced that the Company will participate in two upcoming investor conferences: The Guggenheim Oncology
Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate
MHRA marketing authorizations follow recent European Commission marketing authorizations BRUKINSA is the only treatment authorized for MZL in Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:
Four new indications added for tislelizumab and all nine approved indications now included in NRDL KYPROLIS included for the first time XGEVA successfully renewed BeiGene (NASDAQ: BGNE; HKEX:
Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene